使用所有检查计算的腺瘤检出率与结肠镜检查后结直肠癌风险降低相关:来自新罕布什尔州结肠镜登记处的数据
该队列研究利用新罕布什尔州结肠镜登记处数据,纳入32,535例有指数检查及至少一次随访事件的患者,分析全指征腺瘤检出率(ADR-A)与结肠镜检查后结直肠癌(PCCRC)风险的关系。结果显示ADR-A≥23%各分位组相比<23%参考组PCCRC风险均降低,ADR-A最高四分位(42%+)与筛查ADR最高四分位(35%+)保护作用相似,且ADR-A使95%CI中位收窄28%。作者认为ADR-A可作为质量指标,内镜医师应努力达到44%的目标。
要点
- ADR-A≥23%各分位组相比<23%参考组PCCRC风险降低,HR为0.56至0.32。
- ADR-A最高四分位(42%+)与ADR-S最高四分位(35%+)对PCCRC保护作用相似。
- 使用ADR-A相比ADR-S,内镜医师ADR的95%CI中位收窄28%。
核心结论
- 由全检查计算的ADR较高的内镜医师所行检查,其PCCRC风险较低,有助于验证ADR-A作为质量指标。
- ADR-A可能提高计算ADR的精确性。
- 内镜医师应努力追求更高的ADR-A,以44%为目标。
研究设计与样本
- 基于新罕布什尔州结肠镜登记处的队列研究,纳入有指数检查及至少一次随访事件(结肠镜或结直肠癌诊断)的患者32,535例。
- 结局PCCRC定义为指数检查后≥6个月诊断的任何结直肠癌。
- 暴露变量为内镜医师特异性的全检查ADR(ADR-A),按五分位分组,并与筛查ADR(ADR-S)比较。
- 采用Cox回归模型分析ADR与PCCRC风险,控制年龄、性别及其他协变量。
主要发现
- 共观察到178例PCCRC。
- 与ADR-A<23%参考组相比,ADR-A 23%至<29%组HR=0.56(95%CI:0.36-0.87)。
- 与ADR-A<23%参考组相比,ADR-A 29%至<34%组HR=0.60(95%CI:0.38-0.94)。
- 与ADR-A<23%参考组相比,ADR-A 34%至<44%组HR=0.43(95%CI:0.29-0.65)。
- 与ADR-A<23%参考组相比,ADR-A≥44%组HR=0.32(95%CI:0.16-0.63)。
关键数值与推荐
- ADR-A以23%为参考阈值,≥23%各分位组PCCRC风险均低于<23%组。
- ADR-A最高四分位为42%+,ADR-S最高四分位为35%+。
- 使用ADR-A相比ADR-S,内镜医师ADR的95%CI中位收窄28%(中位=0.72;四分位距(IQR):0.10)。
- 作者提出44%作为ADR-A的追求目标。
临床怎么用
- 作者认为ADR-A有助于验证其作为质量指标,并可能提高计算ADR的精确性。
- 作者建议内镜医师应努力追求更高的ADR-A,以44%为目标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We used New Hampshire Colonoscopy Registry data to examine the association between postcolonoscopy colorectal cancer (PCCRC) risk and an adenoma detection rate (ADR) which was calculated using examinations with all indications, as compared with ADR restricted to only screening examinations. METHODS: Our cohort study included New Hampshire Colonoscopy Registry patients with an index examination and at least 1 follow-up event, either a colonoscopy or a CRC diagnosis. Our outcome, PCCRC, was any CRC diagnosed ≥6 months after an index examination. The exposure variable was endoscopist-specific all-examination ADR (ADR-A), calculated for all indications, divided into quintiles. We also compared the ADR-A with a screening ADR (ADR-S). Cox regression was used to model the hazard of PCCRC on ADR, controlling for age, sex, and other covariates. RESULTS: In 32,535 patients, a lower hazard for PCCRC (n = 178) was observed for ADR-A's ≥ 23%, as compared with ADR-A's <23% (reference) (23% to <29%: hazard ratio (HR) = 0.56, 95% CI: 0.36-0.87; 29% to <34%: HR = 0.60, 95% CI: 0.38-0.94; 34% to <44%: HR = 0.43, 95% CI: 0.29-0.65; and ≥44%: HR = 0.32, 95% CI: 0.16-0.63). The highest quartile of ADR-A (42%+) (HR = 0.41, 95% CI: 0.23-0.75) had a similar protection from PCCRC as the highest quartile of ADR-S (35%+) (HR = 0.38, 95% CI: 0.21-0.70). We observed 95% CIs for ADR's were 28% narrower (median = 0.72; interquartile range (IQR): 0.10) for endoscopists when using ADR-A vs ADR-S. DISCUSSION: Our data demonstrating lower PCCRC risk in examinations performed by endoscopists with higher ADR's calculated with all examinations help to validate ADR-A as a quality measure. ADR-A may also increase precision of the calculated ADR. Endoscopists should strive for a higher ADR-A with 44% as an aspirational target.
引用
- Anderson JC, Rex DK, Mackenzie TA, et al. Adenoma Detection Rates Calculated Using All Examinations Are Associated With Lower Risk for Postcolonoscopy Colorectal Cancer: Data From the New Hampshire Colonoscopy Registry. Am J Gastroenterol. 2025. PMID: 40214109. doi:10.14309/ajg.0000000000003488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。